期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC
1
作者 Wei Rao Yutao Liu +5 位作者 Yan Li Lei Guo Tian Qiu Lin Dong Jianming Ying Weihua Li 《Frontiers of Medicine》 SCIE CSCD 2023年第3期493-502,共10页
Anaplastic lymphoma kinase(ALK)is the most common fusion gene involved in non-small cell lung cancer(NSCLC),and remarkable response has been achieved with the use of ALK tyrosine kinase inhibitors(ALK-TKIs).However,th... Anaplastic lymphoma kinase(ALK)is the most common fusion gene involved in non-small cell lung cancer(NSCLC),and remarkable response has been achieved with the use of ALK tyrosine kinase inhibitors(ALK-TKIs).However,the clinical efficacy is highly variable.Pre-existing intratumoral heterogeneity(ITH)has been proven to contribute to the poor treatment response and the resistance to targeted therapies.In this work,we investigated whether the variant allele frequencies(VAFs)of ALK fusions can help assess ITH and predict targeted therapy efficacy.Through the application of next-generation sequencing(NGS),7.2%(326/4548)of patients were detected to be ALK positive.On the basis of the adjusted VAF(adjVAF,VAF normalization for tumor purity)of four different threshold values(adjVAF<50%,40%,30%,or 20%),the association of ALK subclonality with crizotinib efficacy was assessed.Nonetheless,no statistical association was observed between median progression-free survival(PFS)and ALK subclonality assessed by adjVAF,and a poor correlation of adjVAF with PFS was found among the 85 patients who received first-line crizotinib.Results suggest that the ALK VAF determined by hybrid capture-based NGS is probably unreliable for ITH assessment and targeted therapy efficacy prediction in NSCLC. 展开更多
关键词 ALK fusion next-generation sequencing fluorescence in situ hybridization IMMUNOHISTOCHEMISTRY variant allele frequency intratumoral heterogeneity targeted therapy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部